Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03463408 · ClinicalTrials.gov registry record · Early Phase 1
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
A Early Phase 1 study of Sarcoma, sponsored by University of Rochester.
- Active
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT03463408 is a Early Phase 1 study of Sarcoma that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 14 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03463408, a Early Phase 1 study of Sarcoma, is active but no longer recruiting, sponsored by University of Rochester.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
Conditions Studied
Interventions
- DRUG nivolumab
- DRUG ipilimumab
Study Locations (1)
New York
- James P. Wilmot Cancer Center at University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-07-17 |
| Est. Completion | 2026-08-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03463408
The ClinicalTrials.gov registry entry for NCT03463408 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (98% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which nivolumab is the first listed.
NCT03463408 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03463408 about?
NCT03463408 is a clinical study titled "Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma". Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
What is the current status of trial NCT03463408?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2018-07-17. Estimated completion is 2026-08-01.
What conditions does trial NCT03463408 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT03463408?
The interventions under investigation include: nivolumab (DRUG), ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03463408?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03463408 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
ACTIVE NOT RECRUITING · Early Phase 1
-
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)
ACTIVE NOT RECRUITING · Early Phase 1
-
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
ACTIVE NOT RECRUITING · Early Phase 1
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.